Zobrazeno 1 - 10
of 1 384
pro vyhledávání: '"SGLT2i"'
Autor:
Kazuya Hiura, Chinami Suzuki, Junichi Kubo, Haruka Goto, Shigo Takatori, Kiyomi Ishida, Yuki Tanaka, Akifumi Mizutani, Yuki Yamashita, Chiho Kurumazuka, Akihiko Takagi, Ryu Kobayashi, Akio Shibanami
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been reported to have effects beyond lowering blood glucose levels, with certain SGLT2i expanding their indications to chronic kidney disease and chronic heart failure. We fo
Externí odkaz:
https://doaj.org/article/d0c1771a91af428c8c5076ce837f1f05
Autor:
Matteo Landolfo, Francesco Spannella, Federico Giulietti, Beatrice Ortensi, Lucia Stella, Maria A. Carlucci, Roberta Galeazzi, Federica Turchi, Maria P. Luconi, Roberto Zampa, Sofia Cecchi, Elena Tortato, Massimiliano Petrelli, Riccardo Sarzani
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomatic patients with T
Externí odkaz:
https://doaj.org/article/6e66fc65aabe497f9e169df46d93289a
Autor:
Jonathan J.H. Bray, Marco Coronelli, Sam G.C. Scott, John A. Henry, Liam S. Couch, Mahmood Ahmad, Julian Ormerod, James Gamble, Timothy R. Betts, Andrew Lewis, Oliver J. Rider, Peregrine G. Green, Neil Herring
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 2314-2322 (2024)
Abstract Aims The trials upon which recommendations for the use of cardiac resynchronization therapy (CRT) in heart failure used optimal medical therapy (OMT) before sodium‐glucose co‐transporter 2 inhibitors (SGLT2i). Moreover, the SGLT2i heart
Externí odkaz:
https://doaj.org/article/9c3575e11de544a78cbdd4429daf1d6d
Publikováno v:
Indian Heart Journal, Vol 76, Iss 4, Pp 229-239 (2024)
Novel therapies for heart failure with reduced ejection fraction (HFrEF) are angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose co-transporter 2 inhibitor (SGLT2i), etc. The purpose of this review is to determine the effects of ARNI and
Externí odkaz:
https://doaj.org/article/2d882cf8746c4bb6be1524357dc77b6b
Autor:
David Cherney, Kerstin Folkerts, Paul Mernagh, Mateusz Nikodem, Joerg Pawlitschko, Peter Rossing, Neil Hawkins
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 169-180 (2024)
This study aimed to close an evidence gap concerning the relative efficacy of finerenone versus SGLT2is in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Canagliflozin was selected as a proxy for the SGLT2i class. Patient-level
Externí odkaz:
https://doaj.org/article/dff937541dc9404db1fe3b6590a96398
Autor:
Aleksandra Ryk, Anna Marcinkiewicz, Jędrzej Chrzanowski, Arkadiusz Mariusz Michalak, Izabela Dróżdz, Jacek Burzyński, Michał Krejca, Wojciech Fendler
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background Recently deorphanized G protein-coupled receptor 146 (GPR146) was shown to respond to signal from a newly identified hormone—cholesin—and to play a role in hepatic lipid metabolism. However, the importance of its biological ac
Externí odkaz:
https://doaj.org/article/52c70294f68749b6866fb6b8cab1aa43
Autor:
Nerea Martos-Guillami, Ander Vergara, Carmen Llorens-Cebrià, Aku Enam Motto, Irene Martínez-Díaz, Francisco Gonçalves, Maria Magdalena Garcias-Ramis, Estibaliz Allo-Urzainqui, Alonso Narváez, Sheila Bermejo, Vicent Muñoz, Juan León-Román, Roser Ferrer-Costa, Conxita Jacobs-Cachá, Jordi Vilardell-Vilà, María José Soler
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionDiabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney dis
Externí odkaz:
https://doaj.org/article/7e319ae57f3040b09b2c9a304b365834
Autor:
Michele Correale, Damiano D’Alessandro, Lucia Tricarico, Vincenzo Ceci, Pietro Mazzeo, Raffaele Capasso, Salvatore Ferrara, Massimo Barile, Nicola Di Nunno, Luciano Rossi, Antonio Vitullo, Michele Granatiero, Mattia Granato, Massimo Iacoviello, Natale Daniele Brunetti
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 54, Iss , Pp 101492- (2024)
Background: Cardiac remodeling is an adverse phenomenon linked to heart failure (HF) progression. Cardiac remodeling could represent the real therapeutic goal in the treatment of patients with HF and reduced ejection fraction (HFrEF), being potential
Externí odkaz:
https://doaj.org/article/eb5dd89b2f8547ad8bd2f0ee8fbd728e
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract This study evaluated the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cancer development, particularly in hepatocellular carcinoma (HCC), in individuals with concomitant fatty liver disease (FLD) and type 2 diabetes mellit
Externí odkaz:
https://doaj.org/article/0b2e6bce5904444ab0b15f2958167ef2
Autor:
Hamidreza Soleimani, Behrad Saeedian, Yeganeh Pasebani, Nastaran Babajani, Amirreza Pashapour Yeganeh, Pegah Bahirai, Hossein Navid, Ahmad Amin, Marc D. Samsky, Micheal G. Nanna, Kaveh Hosseini
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 637-648 (2024)
Abstract Sodium–glucose cotransporter‐2 inhibitors (SGLT2is) reduce morbidity and mortality for heart failure (HF) patients and are recommended as cornerstones for their medical therapy. Utilization in clinical practice remains low for multiple r
Externí odkaz:
https://doaj.org/article/3280496dda1741a2afdb5410ae781340